The health news of summer 2026 is marked by three simultaneous fronts: active vector-borne epidemics in the metropolitan territory, the partial entry into force of the European regulation on artificial intelligence applied to care, and a massive but disorderly adoption of generative AI by practitioners. These seemingly distinct topics are reshaping how medical information circulates and how public health decisions are made.
AI Act and health: what has been applicable since August 2026 and what has been postponed
The European regulation on artificial intelligence (AI Act) took a concrete step on August 2, 2026. Since that date, transparency obligations fully apply to AI systems used in the health sector. Every user must be informed when interacting with an AI, whether it is a chatbot for making appointments or a teleconsultation service.
AI-generated content (text, images, audio, video) must also be identifiable, including in online health services. This requirement aims to prevent a patient from confusing an automated response with a human medical opinion.
However, the heaviest obligations have been postponed. A new European regulation that came into force on July 27, 2026, has pushed back the deadline for so-called high-risk AI systems. Triage in emergency departments and automated diagnostic assistance, for example, will only be subject to all requirements starting from December 2, 2027. Medical devices integrating AI benefit from an even longer delay, until August 2, 2028.
To keep up with these regulatory developments and other issues affecting everyday medicine, the news on santeauquotidiencom offers a regularly updated feed.
Generative AI among doctors: frequent use without a hospital framework
A summary published in early August 2026 reveals a concerning figure: 42% of private practitioners report using a generative AI tool at least once a week. The uses are concentrated on administrative tasks, primarily patient file synthesis and report writing.
This rapid adoption is not accompanied by a structured framework. The phenomenon has a name in hospitals: ghost AI. Caregivers use consumer tools (chatbots, writing assistants) without the institution having validated or even identified these practices.
Concrete risks of ghost AI in hospital settings
The problem goes beyond simple compliance issues. When a practitioner copies patient data into an unapproved generative AI tool, several risks accumulate:
- Leakage of health data to servers outside the European Union, in violation of GDPR and certified health data hosting
- Absence of traceability on recommendations or syntheses produced by the AI, which undermines the medical record in case of disputes
- Undetected algorithmic biases, as the tool has not been evaluated on cohorts representative of the French population
Several hospitals have begun drafting internal charters to regulate these uses, but the majority of institutions do not yet have one.
Chikungunya in the metropolitan area and Ebola in the DRC: two monitored epidemic fronts
Summer 2026 saw the emergence of about twenty indigenous cases of chikungunya in the southwest of France. The term indigenous means that these individuals were infected on metropolitan territory, by local mosquitoes, without having traveled to an endemic area. Several mosquito control operations have been conducted in the affected areas.
Chikungunya is transmitted by the tiger mosquito (Aedes albopictus), which is now established in the majority of French departments. The main symptoms are high fevers and intense joint pain, sometimes debilitating for several weeks.
Ebola: a risk of spread deemed high by the WHO
Meanwhile, the Ebola epidemic in the Democratic Republic of the Congo remains classified as “far from being under control” by the World Health Organization. The risk of international spread is considered high.
This situation directly concerns France for two reasons:
- Air connections between the DRC and France are among the most frequent in Europe to Central Africa
- The health monitoring system at the borders, coordinated by Santé publique France, must be maintained at a heightened level of vigilance as long as the epidemic persists
- Isolation protocols in reference health facilities (SAMU, frontline hospitals) have been reactivated accordingly
Melanoma vaccine: results that have reacted in the markets
Among the most commented medical news of the summer, the results of an experimental skin cancer vaccine developed by Moderna caused the laboratory’s stock value to double. The vaccine targets melanoma, the most aggressive form of skin cancer.
These results, described as encouraging by the scientific community, are based on messenger RNA technology similar to that used for Covid-19 vaccines. The principle is to train the patient’s immune system to recognize specific proteins found on tumor cells.
Caution remains essential. Clinical trials are not yet at the final phase of market authorization, and confirmation of long-term benefits will require several years of follow-up. The market reaction reflects more of a signal of hope than a therapeutic certainty.
Summer 2026 illustrates an underlying trend: public health issues are becoming more complex, intertwining technological regulation, field epidemiology, and cutting-edge vaccine research. Keeping up with these news requires cross-referencing specialized sources rather than relying on a single information channel.